Yazan Samhouri, MD
Hematology & Oncology · Gilbert, AZNPI 1124433198
Payments from drug & device makers
Across 279 payments — averaging $2120.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Iovance Biotherapeutics, Inc.$423K
- Merck$47K
- Trillium Therapeutics USA, LLC$43K
- ADC Therapeutics America, Inc.$31K
- Genentech USA, Inc.$12K
- Incyte Corporation$8K
- plus $28K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Iovance Biotherapeutics, Inc. | 93 | $422,853 |
| Merck | 1 | $47,101 |
| Trillium Therapeutics USA, LLC | 4 | $42,929 |
| ADC Therapeutics America, Inc. | 42 | $30,845 |
| Genentech USA, Inc. | 11 | $12,107 |
| Incyte Corporation | 21 | $7,899 |
| Beigene USA, Inc. | 11 | $4,929 |
| Acrotech Biopharma Inc. | 4 | $3,768 |
| Legend Biotech USA Inc. | 4 | $3,226 |
| Epizyme, Inc. | 3 | $3,086 |
| AbbVie | 4 | $2,711 |
| AstraZeneca | 8 | $2,250 |
| Sanofi | 17 | $2,032 |
| Johnson & Johnson(2 entities) | 6 | $1,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $552 |
| Amgen | 5 | $510 |
| E.r. Squibb & Sons, L.L.C. | 6 | $485 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $398 |
| Secura Bio, Inc. | 4 | $357 |
| Bristol Myers Squibb | 3 | $351 |
| Gilead(2 entities) | 4 | $350 |
| Seagen Inc. | 2 | $226 |
| Jazz Pharmaceuticals Inc. | 2 | $195 |
| Kyowa Kirin, Inc. | 3 | $157 |
| Autolus Inc | 1 | $144 |
| Taiho Oncology, Inc. | 1 | $125 |
| Stemline Therapeutics Inc. | 1 | $121 |
| Verastem, Inc. | 1 | $120 |
| Lilly USA, LLC | 1 | $117 |
| Aurobindo Pharma USA, Inc. | 1 | $80 |
| Genentech, Inc. | 1 | $74 |
| Genmab U.S., Inc. | 1 | $45 |
| Bayer | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
How this compares
$591,690 in reported general payments places this provider in the 75th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Gilbert
- Jiaxin NiuGilbert$10.7M
- Sumit MadanGilbert$7.1M
- Hung KhongGilbert$2.8M
- Matthew UlricksonGilbert$1.9M
- Lida MinaGilbert$1.8M
- Horst KlueppelbergGilbert$607K
- Qing ZhaoGilbert$582K
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Sudhir MandaTucson$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.